Managing dermatologic changes of targeted cancer therapy

Kevin Zarrabi; Julie Anne L Gemmill; Maryam Safaee; Lea Baer

Managing dermatologic changes of targeted cancer therapy

J Fam Pract. 2019 Jul/Aug;68(6):334-340.

Authors

Kevin Zarrabi¹, Julie Anne L Gemmill², Maryam Safaee³, Lea Baer⁴

Affiliations

¹ Department of Medicine, Stony Brook University Hospital, NY, USA. Email: Kayvan.zarrabi@gmail.com.
² Department of Medicine, Stony Brook University Hospital, NY, USA.
³ Division of Dermatology, University of Washington, Seattle, USA.
⁴ Department of Medicine, Stony Brook University Hospital, NY; Division of Hematology/Oncology, Department of Medicine, Stony Brook University Hospital, NY, USA.

PMID: 31381621

Abstract

Failure to control these dermatologic changes can lead to lower dosages of cancer agents or an interrupted course of Tx. These steps can help you to head off trouble.

MeSH terms

Antineoplastic Agents / adverse effects*
Drug Eruptions / complications
Drug Eruptions / etiology*
Drug Eruptions / therapy
ErbB Receptors / antagonists & inhibitors
Humans
Molecular Targeted Therapy / adverse effects*
Neoplasms / drug therapy
Stomatitis / chemically induced
Stomatitis / complications
Stomatitis / therapy

Substances

Antineoplastic Agents
ErbB Receptors